1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Maxigen Biotech Inc.

Maxigen Biotech Inc.

TTWSE:1783
36.40
TWD
+0.10
(+0.28%)
3.23EPS
12.03P/E
3.50BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.35
3.03
3.2
4.17
5.33
5.33
5.64
5.7
6.08
6.8
7
7.64
9.05
9.33
Basic EPS, GAAP
0.04
-0.24
-0.77
-0.15
0.2
0.71
0.75
0.79
1.04
1.57
1.86
2.13
2.96
3.24
Free Cash Flow per Basic Share
-1.15
-1.8
-2.9
-0.47
0.28
1.87
0.88
0.79
1.21
2.85
1.67
2.99
2.31
2.71
Dividend per Share
- -
- -
- -
- -
- -
0.14
0.65
0.68
0.67
- -
0.48
1
0.83
- -
Book Value per Share
10.97
10.79
10.14
9.55
9.92
10.51
10.61
10.72
12.84
14.57
15.3
15.42
17.15
16.71
Tangible Book Value per Share
10.96
10.76
10.1
9.5
9.89
10.47
10.58
10.7
12.82
14.56
15.3
15.42
17.14
16.7
Basic Weighted Avg Shares
70
81
82
81
80
80
80
80
84
89
89
89
90
90
Sales/Revenue/Turnover
233
246
261
336
428
428
452
458
512
604
622
681
812
837
Operating Margin (%)
-1.53
-11.64
-23.15
-3.36
4.92
10.79
14.48
13.33
18.16
22.06
24.12
28.56
31.26
31.14
Depreciation Expense
7
7
12
18
26
26
32
33
33
30
28
27
32
37
Net Income, GAAP
3
-19
-63
-12
16
57
60
63
88
139
166
190
265
291
Effective Tax Rate (%)
24.33
- -
- -
- -
5.44
0.44
17.42
17.5
10.05
15.91
14.14
15.69
12.98
10.38
Profit Margin (%)
1.11
-7.75
-24.08
-3.64
3.69
13.34
13.29
13.83
17.12
23.06
26.66
27.94
32.69
34.77
Working Capital
739
593
639
486
490
307
318
345
667
842
488
624
772
706
LT Debt
77
71
65
15
13
- -
12
10
7
- -
- -
- -
- -
- -
Total Equity
888
877
830
781
796
843
851
860
1,142
1,296
1,361
1,375
1,538
1,499
Return on Invested Capital (%)
-0.38
- -
- -
- -
2.47
5.56
6.29
5.73
7.92
8.71
9.5
10.89
14.8
14.94
Return on Capital (%)
0.54
- -
- -
- -
2.45
7.38
7.37
7.31
8.68
11.4
12.48
13.9
17.61
19.33
Return on Common Equity (%)
0.41
-2.16
-7.38
-1.52
2
6.96
7.1
7.4
8.76
11.44
12.48
13.9
18.22
20

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
101
101
102
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
90
90
90
Market Capitalization
3,838
3,793
3,498

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,121
1,180
1,236
Cash, Cash Equivalents & STI
878
951
997
Accounts Receivable, Net
127
120
127
Inventories
99
91
91
Total Current Liabilities
349
356
530
Payables & Accruals
- -
- -
- -
ST Debt
101
101
102
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.81%
12.82%
11.82%
Free Cash Flow
48.99%
45.15%
-22.09%
Net Income, GAAP
13.33%
34.13%
39.52%
Sales/Revenue/Turnover
12.42%
12.3%
19.23%
Total Cash Common Dividend
- -
- -
-16.33%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
127
174
174
206
681
2025
177
209
201
225
812
2026
191
221
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.32
0.66
0.56
0.59
2.13
2025
0.53
0.66
0.84
0.93
2.96
2026
0.59
0.88
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
0.83
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jing Ting Chen
Full Time Employees
127
Sector
Health technology
Industry
Biotechnology
Address
No. 88, Keji 1st Road Taoyuan TP Taiwan 333
IPO Date
May 18, 2011
Website
mbi.com.tw
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Maxigen Biotech Inc. (1783.TW) researches, develops, produces, and sells implantable medical devices and cosmetic products, with a focus on collagen matrix and hyaluronic acid-based biomedical materials; it operates through two primary segments, Biomedical Products and Consumer Products. The company offers core biomedical products including collagen wound dressings (such as HealiAid), collagen membranes (such as FormaAid), collagen plugs, nasal packing (such as NasoAid), and synthetic bone grafts; hyaluronic acid medical devices encompassing intra-articular injections, dermal filler injections, and ophthalmic viscoelastics; as well as beauty care products, skincare items, and functional cosmetics. Maxigen Biotech engages in collagen purification and provides comprehensive OEM/ODM/CDMO services for orthopedic, dental, aesthetic, surgical, ophthalmic, otolaryngology, and wound care applications, serving healthcare providers, distributors, and consumers. Founded in December 1998 and headquartered in Taoyuan City, Taiwan, with manufacturing facilities in New Taipei City, the company conducts operations across Taiwan, the United States, Europe, Asia, South America, Africa, and other international markets; major shareholders include TCI Bio, GIH Group, and NuVasive Inc. In recent developments, Maxigen Biotech relocated its headquarters to Hwa-Ya Technology Park in July 2016, continues to expand its global certifications including CE, FDA, MDSAP, TGA, ISO 13485, ANVISA, NMPA, and KFDA, and maintains a portfolio of 22 privately-owned brand products while pursuing joint sales and customized R&D partnerships worldwide, with no major acquisitions, funding rounds, or strategic shifts reported in the last 1-2 years.